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INTRODUCTION
Breast cancer is one of most common cancers in women and comprises about 23% of all female carcinomas. 1 With regard to histologic subtypes, invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the major two subtypes of invasive carcinoma of the breast. 1 Among the various subtypes, ILC accounts for about 5-15% of all invasive carcinomas, 2,3 and the incidence of ILC has increased more rapidly than that of IDC in the past decade due to widely-prescribed hormone replacement therapy and increasing alcohol consumption. 4, 5 ILC is distinguished from IDC by several clinical and histologic features. For example, ILC usually shows multifocal manifestation and tends to occur in both breasts simultaneously. 6, 7 Histologically, ILC is characterized by discohesive cancer cells lacking E-cadherin expression. 8 Metastatic sites in ILC are often unusual regions including lected at Severance Hospital. Tissue samples were obtained from patients who had undergone breast surgery due to ILC. For the control group, tissue samples were prepared from patients diagnosed with IDC, not otherwise specified from 2006 to 2010. This study was approved by the Institutional Review Board of Severance Hospital. Patients who had received preoperative chemotherapy were excluded from this study. Histologic examination was performed by hematoxylin and eosin (H&E) staining, and all slides were reviewed retrospectively by a trained breast pathologist (Koo JS). The histologic grade was assessed using the Nottingham grading system. 15 Tumor staging was based on the seventh American Joint Committee on Cancer criteria. Diseasefree survival was calculated from the date of the first curative surgery to the date of the first loco-regional or systemic relapse or to death without any type of relapse. Overall survival was estimated from the date of the first curative operation to the date of the last follow-up or death from any cause. Clinicopathologic parameters evaluated in each type of breast cancer included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, distant metastasis, and patient survival.
Tissue microarray
Through retrospective review of the H&E-stained slides, the most appropriate FFPE tumor tissue samples were retrieved, and representative tumor areas were circled on the FFPE blocks. Two 3.0-mm tissue cores were taken from the representative region of each paraffin block and inserted into 6×5 recipient blocks.
Immunohistochemistry
The antibodies used for immunohistochemistry in this the bones, gastrointestinal tract, uterus, meninges, and ovaries, which are rarely involved in cases of IDC. 7, 9, 10 Sarcosine (N-methylglycine) is a non-proteinogenic amino acid that is made during the metabolism and catabolism of glycine. Several major enzymes involved in the sarcosine metabolism pathway include glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and lpipecolic acid oxidase (PIPOX). GNMT participates in the production of sarcosine by transmitting the methyl group from S-adenosylmethionine to glycine. SARDH and PIPOX, both sarcosine-metabolizing enzymes, produce glycine from sarcosine by oxidative demethylation. 11 Sarcosine has been reported as a potential oncometabolite more than nonproteinogenic amino acid. In prostate cancer, sarcosine was studied as a sensitive tumor biomarker and was also found to have a relationship with tumor progression and the metastatic process. 12, 13 Like prostate cancer, breast cancer is hormone-dependent cancer, although in this case, it is predominantly related to estrogen receptor (ER) and progesterone receptor (PR). However, androgen receptor (AR) is also expressed in breast cancer, especially in ILC.
14 In contrast, the expression of sarcosine metabolism-related proteins in breast cancer remains to be elucidated. We aimed to investigate the expression of sarcosine metabolism-related proteins in ILC and IDC, to compare the expression rates in ILC and IDC, and to determine the implications of the results.
MATERIALS AND METHODS

Patient selection and clinicopathologic evaluation
Between January 2000 and December 2012, formalinfixed, paraffin-embedded (FFPE) tissue samples were col- 
RESULTS
Basal characteristics of invasive lobular carcinoma
The clinicopathologic characteristics of patients with ILC are summarized in Table 2 . There were 114 patients with ILC, subdivided into 102 classic-type and 12 pleomorphictype patients. The pleomorphic type showed significant association with older age (p=0.033), a higher nuclear grade (p<0.001), a higher histologic grade (p<0.001), a higher T stage (p=0.026), PR negativity (p=0.005), HER-2 positivity (p=0.002), a higher Ki-67 LI (p<0.001), and the non-luminal A subtype (p<0.001) compared with the classic type.
When comparing clinicopathologic parameters of ILC with those of IDC, ILC was associated with a lower histologic grade (p<0.001), no lymph node metastasis (p=0.026), ER positivity (p<0.001), PR positivity (p<0.001), HER-2 negativity (p<0.001), a lower Ki-67 LI (p<0.001), and a higher incidence of luminal A type (p<0.001) ( Table 3) .
Expression of sarcosine metabolism-related proteins in normal tissue, ILC, and IDC
No difference was observed in the expression of sarcosine metabolism-related proteins between the subtypes of ILC, although expressions of SARDH and PIPOX were higher study are shown in Table 1 . Three-micrometer paraffin sections were deparaffinized and rehydrated by xylene and alcohol solution. Immunohistochemistry was performed using a Ventana Discovery XT automated staining system (Ventana Medical System, Tucson, AZ, USA). Antigen retrieval was performed using CC1 buffer [Cell Conditioning 1; citrate buffer (pH 6.0), Ventana Medical System]. Appropriate positive and negative controls for immunohistochemical staining were also included.
Interpretation of immunohistochemical results
A cut-off value of 1% or more positively-stained nuclei was used to define ER and AR positivity. 16 Human epidermal growth factor receptor-2 (HER-2) staining was analyzed according to the American Society of Clinical Oncology/College of American Pathologists guidelines using the following categories: 0=no immunostaining; 1+=weak incomplete membranous staining in less than 10% of tumor cells; 2+=complete membranous staining either uniform or weak in at least 10% of tumor cells; and 3+=uniform intense membranous staining in at least 30% of tumor cells. 17 HER-2 immunostaining was considered positive when strong (3+) membranous staining was observed whereas cases with 0 to 1+ staining were regarded as negative. The cases showing 2+ HER-2 expression were evaluated for HER-2 amplification by fluorescent in situ hybridization (FISH).
Immunohistochemical markers for GNMT, SARDH, and PIPOX were accessed by light microscopy. Interpretation of immunohistochemical staining for autophagy and redoxrelated proteins was determined by multiplying the proportion of stained cells (0%=0; 1-29%=1; 30-100%=2) by the immunostaining intensity (negative=0; weak=1; moderate=2; strong=3). Final scores of 0-1 were interpreted as negative, and scores of 2-6 were considered positive. 18 The Ki-67 labeling index (LI) was scored by percentage of nuclear stained cells in total tumor cells (0-100%).
Tumor phenotype classification
In this study, we classified breast cancer phenotypes according to the immunohistochemistry results for ER, PR, HER-2, and Ki-67 LI. FISH results for HER-2 were classified as follows:
19 luminal A type: ER and/or PR positive, HER-2 negative, and Ki-67 LI<14%; luminal B type: (HER-2 negative) ER and/or PR positive, HER-2 negative, and Ki-67 LI≥14% and (HER-2 positive) ER and/or PR positive and HER-2 overexpressed or amplified; HER-2 type: ER and PR negative and HER-2 overexpressed or amplified; triple-sarcosine metabolism-related proteins showed different distributions among normal breast tissue, IDC, and ILC (Table  7) . Sarcosine metabolic phenotypes of normal breast tissue were null type (93.3%) and low sarcosine type (6.7%). In IDC, sarcosine metabolic phenotypes were composed of null type (61.7%)>low sarcosine type (30.4%)>high sarcosine type (5.0%)>intermediate type (2.9%); however, in ILC, the proportion of sarcosine metabolic phenotypes was low sarcosine type (61.4%)>null type (32.5%)>intermedi-ate type (5.3%)>high sarcosine type (0.9%) (p<0.001).
in ILC compared to normal tissue (SARDH: p=0.014; PIPOX: p<0.001) ( Table 4) . When comparing ILC with IDC, ILC showed a higher expression of PIPOX (p< 0.001) ( Table 5 , Fig. 1 ). This difference of expression was also observed between ILC and IDC luminal types (p<0.001) ( Table 6 ).
Comparison of sarcosine metabolism phenotypes among normal tissue, IDC, and ILC Sarcosine metabolic phenotypes based on the expression of 
Impact of expression status for sarcosine metabolismrelated proteins on prognosis in ILC
In ILC, no significant association was found between metabolism-related proteins and prognosis with univariate analysis (Table 9 ).
DISCUSSION
The purpose of the present study was to investigate and compare the expressions of sarcosine metabolism-related proteins in ILC and IDC. Compared to IDC, PIPOX had a higher expression rate in ILC (p<0.001). Sarcosine metabolic phenotypes, based on expressions of sarcosine metabolism-related proteins, were found to have different proportional distributions between ILC and IDC. Low sarcosine These different distributions of sarcosine metabolic phenotypes between IDC and ILC were sustained when compared with the sarcosine metabolic phenotypes in luminaltype IDC (p<0.001) ( Table 8) .
Correlation between sarcosine metabolism-related proteins and clinicopathologic factors in ILC
In ILC, PIPOX expression was correlated with AR positivity (p=0.001) (Fig. 2) . In the classical type, PIPOX expression was also correlated with AR positivity (p=0.003), and SARDH expression was associated with a higher T stage (p =0.004). In the pleomorphic type, SARDH expression was correlated with a higher Ki-67 LI (p=0.018) and associated with the luminal A molecular type. All SARDH-positive cases were luminal A molecular type, and all SARDH-negative cases were non-luminal A molecular type (p=0.007). IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. lesions, 11 and elevated sarcosine levels in prostate cancer have also been found. 20 Also, sarcosine elevation is known to be associated with prostate cancer growth and progression in vitro and in vivo. 12 Different sarcosine metabolismrelated proteins and sarcosine metabolic phenotypes in ILC and IDC could result in different tumor biology and behavior between ILC and IDC, as sarcosine has been reported to affect to tumor biology in prostate cancer, although further investigation is required in breast cancer.
In the present study, sarcosine metabolism-related proteins (GNMT, SARDH, and PIPOX) were evaluated instead of sarcosine level measurements in breast cancer tissue. In a prior study, sarcosine levels in prostate cancer tissue were well-correlated with elevated GNMT (a sarcosinegenerating enzyme) and reduced SARDH and PIPOX, both of which are sarcosine-metabolizing enzymes. 12 Considering that ILC in the present study had a higher PIPOX expression rate and more of the low sarcosine phenotype than other types, we expect that a reduced sarcosine level may be found in ILC. However, further validation is needed.
Meanwhile, most of ILC is of the luminal type in molecular classification, whereas IDC is composed of HER-2 and basal-like types, addition to luminal type. In contrast to luminal-type IDC, ILC persistently had a higher PIPOX expression rate and a larger proportion of the low sarcosine phenotype. Thus, in spite of differences of composition of molecular subtypes between ILC and IDC, sarcosine metabolism in ILC and IDC may be unrelated to molecular subtype. In the present study, expression of PIPOX in ILC was correlated with AR positivity (p=0.001), which is incompatible with the previous study on prostate cancer that showed correlation with GNMT expression and AR positivity. 21 This discordance may originate from organ-specific differences; therefore, further study on AR and sarcosine metabolism in ILC is required.
In conclusion, ILC and IDC exhibited different expressions of sarcosine metabolism-related proteins. The low sarcosine type comprised the majority of ILC, and PIPOX expression was dominant in ILC.
